Skip to main content
SpringerLink
Log in

Nonclinical and Clinical Experiences with CPP-Based Self-Assembling Peptide Systems in Topical Drug Development

  • Protocol
  • First Online:
Cell-Penetrating Peptides

Part of the book series: Methods in Molecular Biology ((MIMB,volume 683))

Abstract

Considerations in rational designs of CPP-based transcutaneous delivery systems are described. Impact of design considerations of nonclinical and clinical results are presented in detail.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Scott, A.B. (1981) Botulinum toxin injection of eye muscles to correct strabismus Trans Am Ophthalmol Soc 79, 734–770.

    CAS  PubMed  Google Scholar 

  2. Hallett, M. (1999) One man’s poison-clinical applications of botulinum toxin N Engl J Med 341, 118–120.

    Article  CAS  PubMed  Google Scholar 

  3. Spencer, J.M. (2002) Botulinum Toxin B. The new option in cosmetic injection J Drugs Dermatol 1, 17–22.

    PubMed  Google Scholar 

  4. Carruthers, A. and Carruthers, J. (2005) Botulinum toxin type A J Am Acad Dermatol 53, 284–290.

    Article  PubMed  Google Scholar 

  5. Carruthers, J. and Carruthers, A. (2007) The evolution of botulinum toxin type A for cosmetic applications J Cosmet Laser Ther 9, 186–192.

    Article  PubMed  Google Scholar 

  6. Carruthers, J. and Carruthers, A. (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin J Dermatol Surg Oncol 18,17–21.

    Article  CAS  PubMed  Google Scholar 

  7. Carruthers, J., Fagien, S., Matarasso, S.L., and BOTOX Consensus Group. (2004) Consensus recommendations on the use of botulinum toxin type A in facial aesthetics Plast Reconstr Surg 114:1S–22S.

    Article  PubMed  Google Scholar 

  8. The American Society for Aesthetic Plastic Surgery, Cosmetic Surgery National Data Bank. 2006 statistics. www.surgery.org/download/2006stats.pdf. Accessed 30 March 2007.

  9. Bushara, K.O., Park, D.M., Jones, J.C., and Schutta, H.S. (1996) Botulinum toxin-a possible new treatment for axillary hyperhidrosis Clin Exp Dermatol 21, 276–278.

    Article  CAS  PubMed  Google Scholar 

  10. Schnider, P., Binder, M., Berger, T., and Auff, E. (1996) Botulinum A toxin injection in focal hyperhidrosis Br J Dermatol 134, 1160–1161.

    Article  CAS  PubMed  Google Scholar 

  11. Naumann, M., Hofmann, U., Bergmann, I., Hamm, H., Tiyka, K.V., and Reiners, K. (1998) Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin Arch Dermatol 134, 301–304.

    Article  CAS  PubMed  Google Scholar 

  12. Heckmann, M., Ceballos-Baumann, A.O., and Plewig, G. (2001) Botulinum toxin A for axillary hyperhidrosis (excessive sweating) N Engl J Med 344, 488–493.

    Article  CAS  PubMed  Google Scholar 

  13. Naumann, M. and Lowe, N.J. (2001) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial BMJ 323, 596–599.

    Article  CAS  PubMed  Google Scholar 

  14. Lowe, N.J., Lask, G., Yamauchi, P., and Moore, D. (2002) Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet J Am Acad Dermatol 47, 834–840.

    Article  PubMed  Google Scholar 

  15. Lowe, N.J., Ascher, B., Heckmann, M., Kumar, C., Fraczek, S., and Eadie, N. (2005) BOTOX Facial Aesthetics Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow’s feet Dermatol Surg 31, 257–262.

    Article  CAS  PubMed  Google Scholar 

  16. Matarasso, S.L. and Matarasso, A. (2001) Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids Plast Reconstr Surg 108, 208–214.

    Article  CAS  PubMed  Google Scholar 

  17. Allergan, Inc. (2006) BOTOX Cosmetic (Botulinum Toxin Type A) Prescribing Information. Allergan, Inc., Irvine, CA

    Google Scholar 

  18. Aoki, K.R. and Guyer, B. (2001) Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions Eur J Neurol 8, 21–29.

    Article  PubMed  Google Scholar 

  19. Grumelli, C., Verderio, C., Pozzi, D., Rossetto, O., Montecucco, C., and Matteoli, M. (2005) Internalization and mechanism of action for clostridial toxins in neurons Neurotoxicology 26, 761–767.

    Article  CAS  PubMed  Google Scholar 

  20. Dutton, J.J. and Fowler, A.M. (2007) Botulinum toxin in ophthalmology Surv Ophthalmol 52, 13–31.

    Article  PubMed  Google Scholar 

  21. Ford, K.G., Souberbielle, B.E., Darling, D., and Farzaneh, F. (2001) Protein transduction: an alternative to genetic intervention? Gene Ther 8, 1–4.

    Article  CAS  PubMed  Google Scholar 

  22. Aoki, K.R. (2001) A comparison of the safety margins of botulinum toxin serotypes A, B, and F in mice Toxicon 39, 1815–1820.

    Article  CAS  PubMed  Google Scholar 

  23. Glogau, R.G. (2007) Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study Dermatol Surg 33, S76–S80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Revance Therapeutics Inc, Newark, CA, USA

    Jacob M. Waugh, Jane Lee & Dan Browne

  2. Cardiothoracic Surgery Department, Falk Cardiovascular Research Center, Stanford University School of Medicine, Stanford, CA, USA

    Michael D. Dake

Authors
  1. Jacob M. Waugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael D. Dake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dan Browne
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. , Department of Neurochemistry, Stockholm University, Svante Arrheniusv 21A21A, Stockholm, 106 91, Sweden

    Ãœlo Langel

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Waugh, J.M., Lee, J., Dake, M.D., Browne, D. (2011). Nonclinical and Clinical Experiences with CPP-Based Self-Assembling Peptide Systems in Topical Drug Development. In: Langel, Ü. (eds) Cell-Penetrating Peptides. Methods in Molecular Biology, vol 683. Humana Press. https://doi.org/10.1007/978-1-60761-919-2_39

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-919-2_39

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-918-5

  • Online ISBN: 978-1-60761-919-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation